The economic burden of systemic lupus erythematosus in United Arab Emirates

References

• Justiz Vaillant AA, Goyal A, Varacallo M. Systemic lupus erythematosus. [Updated 2023 Aug 4]. statpearls. [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535405/
   Google Scholar
• Shaikh MF, Jordan N, D'Cruz DP. Systemic lupus erythematosus. Clin Med . 2017;17(1):78–83. doi: 10.7861/clinmedicine.17-1-78.
   PubMed Web of Science ®Google Scholar
• Al Dhanhani AM, Agarwal M, Othman YS, et al. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. Lupus. 2017;26(6):664–669. doi: 10.1177/0961203316678677.
   PubMed Web of Science ®Google Scholar
• Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356. doi: 10.1136/ard-2022-223035.
   PubMed Web of Science ®Google Scholar
• Basta F, Fasola F, Triantafyllias K, et al. Systemic lupus erythematosus (SLE) therapy: the old and the new. Rheumatol Ther. 2020;7(3):433–446. doi: 10.1007/s40744-020-00212-9.
   PubMed Web of Science ®Google Scholar
• Felten R, Sagez F, Gavand PE, et al. 10 Most important contemporary challenges in the management of SLE. Lupus Sci Med. 2019;6(1):e000303. doi: 10.1136/lupus-2018-000303.
   PubMed Web of Science ®Google Scholar
• Kelly A, Crimston-Smith L, Tong A, et al. Scope of outcomes in trials and observational studies of interventions targeting medication adherence in rheumatic conditions: a systematic review. J Rheumatol. 2020;47(10):1565–1574. doi: 10.3899/jrheum.190726.
   PubMed Web of Science ®Google Scholar
• Albrecht K, Redeker I, Aringer M, et al. Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. Lupus Sci Med. 2021;8(1):e000526. doi: 10.1136/lupus-2021-000526.
   PubMed Web of Science ®Google Scholar
• Lin DH, Murimi-Worstell IB, Kan H, et al. Health care utilization and costs of systemic lupus erythematosus in the United States: a systematic review. Lupus. 2022; Jun31(7):773–807. Epub 2022 Apr 25. PMID: 35467448. doi: 10.1177/09612033221088209.
   PubMed Web of Science ®Google Scholar
• Tselios K, Gladman DD, Touma Z, et al. Disease course patterns in systemic lupus erythematosus. Lupus. 2019;28(1):114–122. doi: 10.1177/0961203318817132.
   PubMed Web of Science ®Google Scholar
• Hammond ER, Desta B, Near AM, et al. Near AM, et alFrequency, severeity and costs of flares increase with disease severeity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004. Lupus Sci Med. 2021;8(1):2015Lupus. –e000504. doi: 10.1136/lupus-2021-000504.
   Google Scholar
• Narayanan S, Wilson K, Ogelsby A, et al. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med. 2013;55(11):1262–1270. doi: 10.1097/JOM.0000000000000008.
   PubMed Web of Science ®Google Scholar
• Koelmeyer R, Nim HT, Nikpour M, et al. High disease activity status suggests more severee disease and damage accrual in systemic lupus erythematosusLupus. Lupus Sci Med. 2020;7(1):e000372. doi: 10.1136/lupus-2019-000372.
   PubMed Web of Science ®Google Scholar
• Murimi-Worstell IB, Lin DH, Kan H, et al. Healthcare utilization and costs of systemic lupus erythematosus by disease severeity in the United States. J Rheumatol. 2021;48(3):385–393. doi: 10.3899/jrheum.191187.
   PubMed Web of Science ®Google Scholar
• Gergianaki I, Garantziotis P, Adamichou C, et al. High comorbidity burden in patients with SLE: data from the community-based lupus registry of Crete. J Clin Med. 2021;10(5):998. doi: 10.3390/jcm10050998.
   PubMed Web of Science ®Google Scholar
• AlSaleh J, Jassim V, ElSayed M, et al. Clinical and immunological manifestations in 151 SLE patients living in Dubai. Lupus. 2008;17(1):62–66. doi: 10.1177/0961203307084297.
   PubMed Web of Science ®Google Scholar
• Grabich S, Farrelly E, Ortmann R, et al. Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the medical expenditure panel survey (MEPS) 2016. Lupus Sci Med. 2022;9(1):2018Lupus. –e000640. doi: 10.1136/lupus-2021-000640.
   Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British isles lupus assessment group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology . 2005;44(7):902–906. doi: 10.1093/rheumatology/keh624.
   PubMed Web of Science ®Google Scholar
• The World Bank, Population ages 15-64, total - United Arab Emirates. Retrieved from: https://data.worldbank.org/indicator/SP.POP.1564.TO?locations=AE, in. October, 2023.
   Google Scholar
• The World Bank, Population ages 65 and above, total - United Arab Emirates. Retrieved from: https://data.worldbank.org/indicator/SP.POP.65UP.TO?locations=AE, in. October, 2023.
   Google Scholar
• Chang YS, Huang WN, Tang CH, et al. AB0428 treatment patterns of systemic LUPUS erythematosus patients in Taiwan – a Population-Based analysis annals. Ann Rheum Dis. 2022;81(Suppl 1):1342–1342. doi: 10.1136/annrheumdis-2022-eular.1850.
   Google Scholar
• Nikolopoulos DS, Kostopoulou M, Pieta A, et al. Transition to severee phenotype in systemic lupus erythematosus initially presenting with non-severee disease: implications for the management of early disease. Lupus Sci Med. 2020;7(1):e000394. doi: 10.1136/lupus-2020-000394.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi: 10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. (2012). Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi: 10.1177/0272989X12454577.
   PubMed Web of Science ®Google Scholar
• Chirikov VV, Walker C, Stephens JM, et al. Evaluating the cost-effectiveness of celecoxib versus ibuprofen and naproxen in patients with osteoarthritis in United Arab Emirates based on the PRECISION trial. Clinicoecon Outcomes Res. 2021;13:409–420. doi: 10.2147/CEOR.S280556.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li W, Zhang P, et al. Hematological malignancies in systemic lupus erythematosus: clinical characteristics, risk factors, and prognosis—a case-control study. Arthritis Res Ther. 2022;24(1):5. doi: 10.1186/s13075-021-02692-8.
   PubMed Web of Science ®Google Scholar
• Giannouli S, Voulgarelis M, Ziakas PD, et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis. 2006;65(2):144–148. doi: 10.1136/ard.2005.041673.
   PubMed Web of Science ®Google Scholar
• Aldarmaki R, Al Khogali HI, Al Dhanhani AM. Hospitalization in patients with systemic lupus erythematosus at tawam hospital, United Arab Emirates (UAE): rates, causes, and factors associated with length of stay. Lupus. 2021;30(5):845–851. doi: 10.1177/0961203321990086.
   PubMed Web of Science ®Google Scholar
• Namas R, Qassimi SA, Malik A, et al. LP-133 Baseline clinical characteristics of SLE patients compared to those with lupus nephritis and on renal replacement treatment (RRT) including kidney transplantation. Lupus Sci Med. 2023;10(Suppl 1):A136–A137.
   Google Scholar
• Al-Attia HM, George S. Characterization of systemic lupus erythematosus in patients in U.A.E. Clin Rheumatol. 1995;14(2):171–175. doi: 10.1007/BF02214938.
   PubMed Web of Science ®Google Scholar
• Alhammadi NA, Alqahtani H, Alshahrani LH, et al. Cardiovascular complications in lupus patients in the Aseer Region, Saudi Arabia. Cureus. 2023;15(8):e43501. doi: 10.7759/cureus.43501.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-Stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432–1441. doi: 10.1002/art.39594.
   PubMed Web of Science ®Google Scholar
• Ko T, Koelmeyer R, Li N, et al. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis. Semin Arthritis Rheum. 2022;57:152099. doi: 10.1016/j.semarthrit.2022.152099.
   PubMed Web of Science ®Google Scholar
• The World Bank, Gender Data Portal. Retrieved from: https://genderdata.worldbank.org/countries/united-arab-emirates/,. in October, 2023.
   Google Scholar
• Drenkard C, Bao G, Dennis G, et al. Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States. Arthritis Care Res . 2014;66(6):878–887. doi: 10.1002/acr.22245.
   Web of Science ®Google Scholar
• Utset TO, Baskaran A, Segal BM, et al. Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. Lupus Sci Med. 2015;2(1):e000058–e000058. doi: 10.1136/lupus-2014-000058.
   PubMedGoogle Scholar
• The World Bank, GDP per capita (current LCU) United Arab Emirates. Retrieved from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CN?locations=1W-AE, in. October, 2023.
   Google Scholar
• Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1(4):163–175. doi: 10.1177/2040622310380100.
   PubMedGoogle Scholar
• Karim MY, Alba P, Cuadrado M‐J, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology. 2002;41(8):876–882. doi: 10.1093/rheumatology/41.8.876.
   PubMed Web of Science ®Google Scholar
• Porta S, Danza A, Arias Saavedra M, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9(9):2709. doi: 10.3390/jcm9092709.
   PubMed Web of Science ®Google Scholar
• Kernder A, Richter JG, Fischer-Betz R, et al. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the LuLa cohort. Lupus. 2021;30(3):431–438. doi: 10.1177/0961203320983445.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Daly RP, Foster SA, et al. The caregiver burden in lupus: findings from UNVEIL, a national online lupus survey in the United States. Lupus. 2017;26(1):54–61. doi: 10.1177/0961203316651743.
   PubMed Web of Science ®Google Scholar
• Fatoye F, Gebrye T, Svenson LW. Direct health system costs for systemic lupus erythematosus patients in Alberta, Canada. PLOS One. 2021;16(5):e0251409. doi: 10.1371/journal.pone.0251409.
   PubMed Web of Science ®Google Scholar
• Slawsky KA, Fernandes AW, Fusfeld L, et al. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res. 2011;63(9):1224–1232. doi: 10.1002/acr.20502.
   Web of Science ®Google Scholar
• Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus. 2010;19(10):1250–1255. doi: 10.1177/0961203310373780.
   PubMed Web of Science ®Google Scholar
• Schwarting A, Friedel H, Garal-Pantaler E, et al. The burden of systemic lupus erythematosus in Germany: incidence, prevalence, and healthcare resource utilization. Rheumatol Ther. 2021;8(1):375–393. doi: 10.1007/s40744-021-00277-0.
   PubMed Web of Science ®Google Scholar
• Segura BT, Bernstein BS, McDonnell T, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology . 2020;59(3):698–698. doi: 10.1093/rheumatology/kez516.
   PubMed Web of Science ®Google Scholar
• Murimi-Worstell IB, Lin DH, Nab H, et al. Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis. BMJ Open. 2020;10(5):e031850. doi: 10.1136/bmjopen-2019-031850.
   PubMed Web of Science ®Google Scholar
• Barber MRW, Hanly JG, Su L, et al. Economic evaluation of damage accrual in an international systemic lupus erythematosus inception cohort using a multistate model approach. Arthritis Care Res . 2020;72(12):1800–1808. doi: 10.1002/acr.24092.
   Web of Science ®Google Scholar
• Bell CF, Huang SP, Cyhaniuk A, et al. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus. 2023;32(2):301–309. doi: 10.1177/09612033221146093.
   PubMed Web of Science ®Google Scholar
• Hanly JG, O'Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology . 2016;55(2):252–262. doi: 10.1093/rheumatology/kev311.
   PubMed Web of Science ®Google Scholar
• The Economic Burden of Systemic Lupus Erythematosus in Mexico. Taiwan, Colombia, and Malaysia. Submitted work to Journal of Medical Economics 2024 (under publication).
   Google Scholar